MedTrace Logo

Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors

NCT03112694 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 93

Last updated 2020-06-02

No results posted yet for this study

Summary

The purpose of this study is to understand how people with neuroendocrine tumors respond to treatment with lanreotide after having received treatment with octreotide.

Conditions

Interventions

OTHER

Data collection

This is a non-interventional study, the decision to prescribe the product would have been taken prior to, and independently from the decision to enrol the patient.

Sponsors & Collaborators

Principal Investigators

  • Ipsen Medical Director · Ipsen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-04
Primary Completion
2017-11-02
Completion
2017-11-02

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03112694 on ClinicalTrials.gov